EGFR and breast carcinoma: This is because the Her-2-ER interaction is also associated with the anti-hormone resistance [43, 44] and PTPH1 can decrease Her-2/Y877 phosphorylation (data not shown) and increase breast cancer sensitivity to the EGFR/Her-2 dual inhibitor Lap (Figure 2).